-
Mashup Score: 17P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study - 8 month(s) ago
Abstract Background After a brief period of dual antiplatelet therapy, P2Y12 inhibitor monotherapy in the absence of aspirin effectively reduces bleeding without increasing recurrent ischemia in pa…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 6C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander? - 1 year(s) ago
This editorial refers to ‘Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein’, by P.E. Thomas et al., http
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander? - 1 year(s) ago
This editorial refers to ‘Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein’, by P.E. Thomas et al., http
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander? - 1 year(s) ago
This editorial refers to ‘Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein’, by P.E. Thomas et al., http
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein - 1 year(s) ago
AbstractAims. Recent evidence suggest that the lipoprotein(a)-associated risk of atherosclerotic cardiovascular disease (ASCVD) may be observed only in individu
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Open SBIR/STTR Funding Opportunities | National Institute on Alcohol Abuse and Alcoholism (NIAAA) - 1 year(s) ago
Open Funding Opportunities Omnibus Solicitation NIAAA offers funding through the PHS 2022-2 Omnibus Solicitation program announcement, as well as targeted Funding Opportunity Announcements (FOAs) and several resources for additional technical assistance, commercialization R&D support, and training programs. Standard due dates are April 5, September 5, and January 5 or the next business day.
Source: www.niaaa.nih.govCategories: Addiction Medicine, Latest HeadlinesTweet-
#DYK that #NIAAAsbir & #STTR Phase I #awardees are eligible for the Commercialization Readiness Pilot Program? #CRP provides funding and technical assistance to develop regulatory strategy and more. Learn more about #CRP and other awardee #opportunties: https://t.co/NqAHicdZbs https://t.co/EIw00stxNz
-
-
Mashup Score: 2Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, OBGYNTweet
-
Mashup Score: 8
The relation between serial high-sensitivity C-reactive protein (hsCRP) and long-term major cardiovascular events (MACEs; cardiovascular death, myocar…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7
AbstractAims. Hyperlipidaemia and inflammation jointly contribute to atherosclerotic disease. Yet, after the initiation of statin therapy, the relative contribu
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 11Periodontal Status, C-Reactive Protein, NT-proBNP, and Incident Heart Failure: The ARIC Study - 2 year(s) ago
Abstract Background Periodontal disease (PD), resulting from inflammatory host response to dysbiotic subgingival microbiota, has been linked to cardiovascular disease; however, its relationship to …
Source: JACC: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet
The #MACT pilot study shows combining #P2Y12 inhibitor monotherapy (ticagrelor/prasugrel) w/ colchicine post-#PCI in #ACS pts results in favorable platelet reactivity, & slashes high #CRP / inflammation by a whopping 70%. https://t.co/viDoSJoRAi #JACCINT #cvACS #CardioTwitter https://t.co/eF7BmFOVz2